We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+25.85%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$148M
AUM Growth
+$11.9M
Cap. Flow
-$3.01M
Cap. Flow %
-2.04%
Top 10 Hldgs %
61.6%
Holding
48
New
13
Increased
13
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$4.95M
2
PRAX icon
Praxis Precision Medicines
PRAX
+$4.34M
3
CLNN icon
Clene
CLNN
+$4.14M
4
IMA
ImageneBio Inc
IMA
+$3.33M
5
IMVT icon
Immunovant
IMVT
+$2.64M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$5.26M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$5.26M
3
BLU
BELLUS Health Inc.
BLU
+$4.55M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$4.52M
5
CBAY
Cymabay Therapeutics
CBAY
+$4.18M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 2.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
APLS
1
DELISTED
Apellis Pharmaceuticals
APLS
$27.1M 18.37%
297,596
+7,096
+2% +$612K
WHWK
2
Whitehawk Therapeutics
WHWK
$196M
$12.6M 8.57%
1,849,402
– –
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$8.49M 5.75%
970,000
-129,309
-12% -$1.51M
KURA icon
4
Kura Oncology
KURA
$816M
$7.5M 5.08%
709,118
+143,861
+25% +$1.7M
SNDX icon
5
Syndax Pharmaceuticals
SNDX
$1.7B
$6.28M 4.25%
299,841
-30,159
-9% -$628K
IRON icon
6
Disc Medicine
IRON
$2.93B
$6.19M 4.2%
+139,500
New +$4.95M
PCVX icon
7
Vaxcyte
PCVX
$7.73B
$6.1M 4.13%
122,166
+1,666
+1% +$79K
RCKT icon
8
Rocket Pharmaceuticals
RCKT
$372M
$6.08M 4.12%
306,194
+8,194
+3% +$166K
VRDN icon
9
Viridian Therapeutics
VRDN
$2.13B
$5.35M 3.62%
224,707
+56,707
+34% +$1.45M
ISEE
10
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.17M 3.5%
131,454
-149,046
-53% -$5.26M
ARGX icon
11
argenx
ARGX
$52B
$4.9M 3.32%
12,568
+2,974
+31% +$1.17M
PRAX icon
12
Praxis Precision Medicines
PRAX
$8.52B
$4.89M 3.31%
+283,333
New +$4.34M
VTYX
13
DELISTED
Ventyx Biosciences
VTYX
$4.83M 3.27%
147,318
-61,182
-29% -$2.11M
CBAY
14
DELISTED
Cymabay Therapeutics
CBAY
$4.71M 3.19%
430,000
-448,500
-51% -$4.18M
CLDX icon
15
Celldex Therapeutics
CLDX
$2.96B
$4.15M 2.81%
122,343
+843
+0.7% +$28.4K
CLNN icon
16
Clene
CLNN
$66.3M
$3.73M 2.53%
+212,042
New +$4.14M
IMA
17
ImageneBio Inc
IMA
$64.2M
$3.66M 2.48%
+46,500
New +$3.33M
EYPT icon
18
EyePoint Inc
EYPT
$1.04B
$3.32M 2.25%
382,000
+78,604
+26% +$480K
GHRS icon
19
GH Research
GHRS
$1.93B
$2.9M 1.97%
244,828
+1,578
+0.6% +$16.2K
IMVT icon
20
Immunovant
IMVT
$7.91B
$2.69M 1.82%
+141,755
New +$2.64M
VSTM icon
21
Verastem
VSTM
$500M
$2.23M 1.51%
+300,000
New +$2.08M
ROIV icon
22
Roivant Sciences
ROIV
$24.1B
$2.22M 1.5%
+220,000
New +$1.97M
ELVN icon
23
Enliven Therapeutics
ELVN
$4.15B
$2.13M 1.45%
104,500
+73,521
+237% +$1.49M
ALKS icon
24
Alkermes
ALKS
$8.31B
$1.4M 0.95%
44,689
+13,000
+41% +$394K
ACRS icon
25
Aclaris Therapeutics
ACRS
$772M
$1.26M 0.86%
121,692
-148
-0.1% -$1.34K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2023 Portfolio in Review

As of Q2 2023, Acuta Capital Partners held 48 positions worth $148M, up 8.7% from $136M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners's Q2 2023 filing shows 13 new, 13 increased, 7 reduced and 13 closed positions. Its largest new stake was Disc Medicine: 139,500 shares worth $6.19M. The largest sale was United Therapeutics, an estimated $5.26M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Consumer Staples.

  • Acuta Capital Partners's largest Q2 2023 buy was Disc Medicine: 139,500 shares worth $6.19M.
  • Acuta Capital Partners added most to Kura Oncology in Q2 2023, an estimated $1.7M increase.
  • Acuta Capital Partners's biggest Q2 2023 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $5.26M.
  • Acuta Capital Partners fully exited United Therapeutics in Q2 2023, selling an estimated $5.26M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $148M portfolio in Q2 2023.
  • Acuta Capital Partners opened 13 new positions and closed 13 in Q2 2023.
  • Acuta Capital Partners's portfolio value rose 8.7% quarter-over-quarter to $148M.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.